Dramatic response to alectinib in a patient with ALK‐rearranged squamous cell lung cancer

Abstract Lung cancers with anaplastic lymphoma kinase (ALK) rearrangements are highly sensitive to treatment with ALK tyrosine kinase inhibitors (TKIs). Due to the very low rate of patients with squamous cell carcinoma enrolled in clinical trials, the efficacy of ALK inhibitors in patients with ALK‐...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Jun Shiihara, Fumiyoshi Ohyanagi, Hikari Amari, Minemichi Toda, Hiroki Tahara, Motoi Yuzawa, Yuki Maeda, Motoko Nomura, Yoshiko Mizushina, Yoshiaki Nagai, Hiromitsu Ohta, Yasuhiro Yamaguchi
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Wiley 2021-09-01
Serie:	Thoracic Cancer
Ämnen:	alectinib anaplastic lymphoma kinase lung cancer squamous cell cancer
Länkar:	https://doi.org/10.1111/1759-7714.14092
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!